<DOC>
	<DOCNO>NCT01284920</DOCNO>
	<brief_summary>This study evaluate safety , tolerability pharmacokinetics efficacy MDV3100 oral administration patient castration-resistant prostate cancer .</brief_summary>
	<brief_title>A Study MDV3100 Evaluate Safety , Tolerability , Pharmacokinetics Efficacy Prostate Cancer Patients</brief_title>
	<detailed_description>This Phase1/2 , open-label , uncontrolled study , involve Dose-Escalation Cohorts , dose escalate next dose safety , tolerability , PK evaluate metastatic castration-resistant prostate cancer ( mCRPC ) patient Expansion Cohort , efficacy , safety , PK MDV3100 post-chemo mCRPC patient evaluate . After evaluation safety tolerability Dose-Escalation Cohorts , additional patient include Expansion Cohort .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Histologically cytologically confirm adenocarcinoma prostate Ongoing androgen deprivation therapy GnRH analogue bilateral orchiectomy Progressive disease prior androgen deprivation therapy ( medical surgical castration ) For Expansion Cohort , patient two prior chemotherapy regimen least one regimen contain docetaxel For Expansion Cohort , patient must measurable lesion RECIST Metastases brain History another malignancy except adenocarcinoma prostate within previous 5 year Use bicalutamide within 6 week prior study Radiation therapy within 12 week prior study Evidence serious drug hypersensitivity</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>MDV3100</keyword>
	<keyword>Response Evaluation Criteria Solid Tumor ( RECIST )</keyword>
	<keyword>docetaxel</keyword>
	<keyword>PSA level</keyword>
</DOC>